TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04047095

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrients + normal daily meal
Description: Glutamine Plus by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal daily meal
Description: Normal daily meal (75-80 g protein)
Study: NCT03062566

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
Study: NCT04526496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTP-198, single dose
Description: Single dose of FTP-198, 6 dose levels, oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, single dose
Description: Placebo matched to FTP-198, oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTP-198, multiple doses
Description: Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, multiple doses
Description: Placebo matched to FTP-198, oral suspension, 7 days
Study: NCT03778905

Intervention type: OTHER
Intervention: Rehabilitation
Description: The stroke patients who admitted to post acute care(PAC) institution would undergo regular rehabilitation.
Study: NCT04646109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 5mg/5ml solution was manufactured by NEUTEC™ Pharmaceutical Company-Turkey, under Good Manufacturing Practices (GMP) certification conditions.
Study: NCT02892500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine hydrochloride and betamethasone sodium phosphate
Description: 5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine hydrochloride
Description: 5ml of bupivacaine hydrochloride into the tibiofibular ligament
Study: NCT03855475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Participants will complete 12 weeks of supervised aerobic exercise, 3 times per week, on a treadmill or stationary bicycle

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants will complete 12 weeks of supervised stretching, 3 times per week
Study: NCT01743378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block Ropivacaine 0,75 %

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP Block Saline 0,9 %
Study: NCT05520788

Intervention type: GENETIC
Intervention: precise medicine
Description: During screening stage, all patients should accept next-generation sequencing (NGS) test.
Study: NCT04266210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji Bulk
Description: Restorative system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-ænial Posterior
Description: Restorative system
Study: NCT01171690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
Study: NCT03571048

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reduced Calorie Diet (RCD)
Description: Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced Calorie Diet (RCD)
Description: Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding (TRF)
Description: Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.
Study: NCT00592098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strontium chloride hexahydrate
Description: Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
Study: NCT03673488

Intervention type: DEVICE
Intervention: TephaFlex™ mid-urethral sling
Description: The sling is made from P4HB material. It is placed in a similar technique to standard retropubic sling procedures, but will resorb over 18-24 months post surgery.
Study: NCT04281563

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: massage with MCT oil (group 1)
Description: Two trained nurse took turns performing standardized massage techniques in group 1 and group 2. The difference was that in group 1, the neonates received massage with MCT oil, and in group 2, the neonates received massage without using the oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation (13), which were given three times a day for 7 consecutive days. The massage force was approximately 300 grams, and the massager practiced applying the pressure by using a food scale. The massage was given in the prone and supine positions, and the actions included gentle touching of the head, back and limbs for five 1-min periods, followed by six passive flexion/extension movements lasting 10 s apiece for each arm, then each leg, and finally both legs together for a total of five 1-min periods. Premature infants in the oil massage group received massage with 10 mL/kg/day of MCT oil divided equally into three applications.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage with MCT oil (group 1)
Description: Two trained nurse took turns performing standardized massage techniques in group 1 and group 2. The difference was that in group 1, the neonates received massage with MCT oil, and in group 2, the neonates received massage without using the oil. The 10-min massage intervention consisted of two 5-min phases: tactile and kinesthetic stimulation (13), which were given three times a day for 7 consecutive days. The massage force was approximately 300 grams, and the massager practiced applying the pressure by using a food scale. The massage was given in the prone and supine positions, and the actions included gentle touching of the head, back and limbs for five 1-min periods, followed by six passive flexion/extension movements lasting 10 s apiece for each arm, then each leg, and finally both legs together for a total of five 1-min periods. Premature infants in the oil massage group received massage with 10 mL/kg/day of MCT oil divided equally into three applications.
Study: NCT02107300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeutraSal
Description: NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
Study: NCT04522609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of warm-up and warm-down. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation: 5-6 session per week, for 12 weeks, with 60-minuite session.
Study: NCT04448678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Insurance Education Program (HIEP)
Description: \[See arm/group descriptions\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: \[See arm/group descriptions\]
Study: NCT06389409

Intervention type: OTHER
Intervention: Observation of testicular cancer patients
Description: Collection of clinical data of all patients suffering from neoplastic testicular pathology undergoing surgery
Study: NCT03361228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat at the protocol-defined dose administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat at the protocol-defined dose administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at the protocol-defined dose administered intravenously every 3 weeks.
Study: NCT00302952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
Study: NCT02136095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative fluorescent cholangiography (IFC)
Description: A standardized protocol with IFC including concomitant angiography was performed during laparoscopic cholecystectomy.
Study: NCT05455073

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weekly Iron and Folic Acid Supplementation (WIFA)
Description: Weekly school provision of WIFA tablets to adolescent girls

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weekly Iron and Folic Acid Supplementation (WIFA)
Description: Weekly school provision of WIFA tablets to adolescent girls

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: WASH
Description: Ensure availability (or provision) of water, sanitation, and hygiene supplies for adolescent girls and boys

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Menstrual Hygiene Management
Description: Support for adolescent girls' menstrual hygiene

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Behavior Change Intervention (BCI)
Description: Changing the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Behavior Change Intervention (BCI)
Description: Changing the knowledge, attitudes, and practices of nutrition (including dietary diversity), IFA, deworming

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MHM & WASH Behavior Change Intervention (BCI)
Description: Changing the knowledge, attitudes, and practices of WASH and menstrual hygiene management
Study: NCT01936948

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clip closure
Description: Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clip closure
Description: Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
Study: NCT02365207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG strain of Mycobacterium bovis
Description: Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
Study: NCT05504603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib and rituximab
Description: zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1,8,15,22. Other name: Part A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib and rituximab
Description: zanubrutinib 160mg PO BID d1-28; rituximab 375mg/m2 IVGTT d1. Other name: Part B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM pretreatment
Description: semustine 250mg/m2 PO d1; etoposide 200mg/m2 IV d2-5; cytarabine 400mg/m2 IV d2-5; melphalan 140mg/m2 IV d6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib maintenance
Description: zanubrutinib 160mg PO BID.
Study: NCT01092351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: 100 mg retard capsules to be taken twice daily for seven days
Study: NCT02582541

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SEMS alone
Description: The SEMS (Wallstent, Boston Scientific, USA) would be placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SEMS plus radiofrequency ablation
Description: The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
Study: NCT01988922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 0.4 mg/kg oral racemic ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 0.4 mg/kg oral racemic ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 0.4 mg/kg oral racemic ketamine
Study: NCT02968186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation program
Description: Health professionals in the intervention arm will receive up to four training sessions in the first three months of the implementation period. Practice support will be continuously available throughout the project. Posters specifically designed for this project will be added to the primary health care units aiming to facilitate eliciting alcohol issues during the consultations, and to help professionals remembering to conduct alcohol screening and brief intervention. Leaflets to be handed-in to patients were also specifically produced for this project, aiming to aid professionals in advising at-risk drinkers to cut down. The research team will schedule with each primary health care unit regular visits for feedback on the progress of the program.
Study: NCT03432845

Intervention type: OTHER
Intervention: compare reversal agents
Description: compare effect of two different approved reversal agents on postoperative and post-discharge nausea and vomiting

Intervention type: OTHER
Intervention: compare reversal agents
Description: compare effect of two different approved reversal agents on postoperative and post-discharge nausea and vomiting
Study: NCT03116386

Intervention type: OTHER
Group type: OTHER
Intervention: run-in period
Description: observational time i.e. baseline situation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control period
Description: neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etolya-F ® devices
Description: Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
Study: NCT01674556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: Gemcitabine in combination with ultrasound (US) contrast agent under sonication
Study: NCT05845996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344
Description: Solution for intravenous/subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Solution for intravenous/subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin
Description: Subcutaneous Lyophilized powder for reconstitution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Keyhole limpet hemocyanin
Description: Subcutaneous Lyophilized powder for reconstitution
Study: NCT05293990

Intervention type: RADIATION
Group type: OTHER
Intervention: Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
Description: Usefulness of Gadovist-enhanced FLAIR imaging in differentiation between a glioblastoma and solitary brain metastasis
Study: NCT01278056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exjade
Description: Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
Study: NCT00163449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Efficacy and Safety of Ciclesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Efficacy and Safety of Ciclesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Efficacy and Safety of Ciclesonide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04480788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell injection targeting CD7 chimeric antigen receptor
Description: Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation
Study: NCT04453748

Intervention type: OTHER
Intervention: Complex diagnostic panel
Description: Complex, multidisciplinary diagnostic panel, including blood, imaging and functional tests.
Study: NCT03156062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroids with salicylic acid
Description: comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids with salicylic acid
Description: comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis
Study: NCT01520948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-based behavioral therapy
Description: Pelvic floor muscle exercise training, bladder training, fluid management, constipation management

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral control
Description: Mirrored star drawing
Study: NCT01734291

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family psychoeducation
Description: Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Family psychoeducation
Description: Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians
Study: NCT03266237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxigrip®
Description: To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxigrip®
Description: To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxigrip®
Description: To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxigrip®
Description: To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.
Study: NCT02238145

Intervention type: DRUG
Intervention: Atrovent® Inhaletten
Study: NCT03482882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)